Cargando…
Pharmacological and Physiological Characterization of the Tremulous Jaw Movement Model of Parkinsonian Tremor: Potential Insights into the Pathophysiology of Tremor
Tremor is a cardinal symptom of parkinsonism, occurring early on in the disease course and affecting more than 70% of patients. Parkinsonian resting tremor occurs in a frequency range of 3–7 Hz and can be resistant to available pharmacotherapy. Despite its prevalence, and the significant decrease in...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131529/ https://www.ncbi.nlm.nih.gov/pubmed/21772815 http://dx.doi.org/10.3389/fnsys.2011.00049 |
_version_ | 1782207725791346688 |
---|---|
author | Collins-Praino, Lyndsey E. Paul, Nicholas E. Rychalsky, Kristen L. Hinman, James R. Chrobak, James J. Senatus, Patrick B. Salamone, John D. |
author_facet | Collins-Praino, Lyndsey E. Paul, Nicholas E. Rychalsky, Kristen L. Hinman, James R. Chrobak, James J. Senatus, Patrick B. Salamone, John D. |
author_sort | Collins-Praino, Lyndsey E. |
collection | PubMed |
description | Tremor is a cardinal symptom of parkinsonism, occurring early on in the disease course and affecting more than 70% of patients. Parkinsonian resting tremor occurs in a frequency range of 3–7 Hz and can be resistant to available pharmacotherapy. Despite its prevalence, and the significant decrease in quality of life associated with it, the pathophysiology of parkinsonian tremor is poorly understood. The tremulous jaw movement (TJM) model is an extensively validated rodent model of tremor. TJMs are induced by conditions that also lead to parkinsonism in humans (i.e., striatal DA depletion, DA antagonism, and cholinomimetic activity) and reversed by several antiparkinsonian drugs (i.e., DA precursors, DA agonists, anticholinergics, and adenosine A(2A) antagonists). TJMs occur in the same 3–7 Hz frequency range seen in parkinsonian resting tremor, a range distinct from that of dyskinesia (1–2 Hz), and postural tremor (8–14 Hz). Overall, these drug-induced TJMs share many characteristics with human parkinsonian tremor, but do not closely resemble tardive dyskinesia. The current review discusses recent advances in the validation of the TJM model, and illustrates how this model is being used to develop novel therapeutic strategies, both surgical and pharmacological, for the treatment of parkinsonian resting tremor. |
format | Online Article Text |
id | pubmed-3131529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Frontiers Research Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-31315292011-07-19 Pharmacological and Physiological Characterization of the Tremulous Jaw Movement Model of Parkinsonian Tremor: Potential Insights into the Pathophysiology of Tremor Collins-Praino, Lyndsey E. Paul, Nicholas E. Rychalsky, Kristen L. Hinman, James R. Chrobak, James J. Senatus, Patrick B. Salamone, John D. Front Syst Neurosci Neuroscience Tremor is a cardinal symptom of parkinsonism, occurring early on in the disease course and affecting more than 70% of patients. Parkinsonian resting tremor occurs in a frequency range of 3–7 Hz and can be resistant to available pharmacotherapy. Despite its prevalence, and the significant decrease in quality of life associated with it, the pathophysiology of parkinsonian tremor is poorly understood. The tremulous jaw movement (TJM) model is an extensively validated rodent model of tremor. TJMs are induced by conditions that also lead to parkinsonism in humans (i.e., striatal DA depletion, DA antagonism, and cholinomimetic activity) and reversed by several antiparkinsonian drugs (i.e., DA precursors, DA agonists, anticholinergics, and adenosine A(2A) antagonists). TJMs occur in the same 3–7 Hz frequency range seen in parkinsonian resting tremor, a range distinct from that of dyskinesia (1–2 Hz), and postural tremor (8–14 Hz). Overall, these drug-induced TJMs share many characteristics with human parkinsonian tremor, but do not closely resemble tardive dyskinesia. The current review discusses recent advances in the validation of the TJM model, and illustrates how this model is being used to develop novel therapeutic strategies, both surgical and pharmacological, for the treatment of parkinsonian resting tremor. Frontiers Research Foundation 2011-07-04 /pmc/articles/PMC3131529/ /pubmed/21772815 http://dx.doi.org/10.3389/fnsys.2011.00049 Text en Copyright © 2011 Collins-Praino, Paul, Rychalsky, Hinman, Chrobak, Senatus and Salamone. http://www.frontiersin.org/licenseagreement This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and other Frontiers conditions are complied with. |
spellingShingle | Neuroscience Collins-Praino, Lyndsey E. Paul, Nicholas E. Rychalsky, Kristen L. Hinman, James R. Chrobak, James J. Senatus, Patrick B. Salamone, John D. Pharmacological and Physiological Characterization of the Tremulous Jaw Movement Model of Parkinsonian Tremor: Potential Insights into the Pathophysiology of Tremor |
title | Pharmacological and Physiological Characterization of the Tremulous Jaw Movement Model of Parkinsonian Tremor: Potential Insights into the Pathophysiology of Tremor |
title_full | Pharmacological and Physiological Characterization of the Tremulous Jaw Movement Model of Parkinsonian Tremor: Potential Insights into the Pathophysiology of Tremor |
title_fullStr | Pharmacological and Physiological Characterization of the Tremulous Jaw Movement Model of Parkinsonian Tremor: Potential Insights into the Pathophysiology of Tremor |
title_full_unstemmed | Pharmacological and Physiological Characterization of the Tremulous Jaw Movement Model of Parkinsonian Tremor: Potential Insights into the Pathophysiology of Tremor |
title_short | Pharmacological and Physiological Characterization of the Tremulous Jaw Movement Model of Parkinsonian Tremor: Potential Insights into the Pathophysiology of Tremor |
title_sort | pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131529/ https://www.ncbi.nlm.nih.gov/pubmed/21772815 http://dx.doi.org/10.3389/fnsys.2011.00049 |
work_keys_str_mv | AT collinsprainolyndseye pharmacologicalandphysiologicalcharacterizationofthetremulousjawmovementmodelofparkinsoniantremorpotentialinsightsintothepathophysiologyoftremor AT paulnicholase pharmacologicalandphysiologicalcharacterizationofthetremulousjawmovementmodelofparkinsoniantremorpotentialinsightsintothepathophysiologyoftremor AT rychalskykristenl pharmacologicalandphysiologicalcharacterizationofthetremulousjawmovementmodelofparkinsoniantremorpotentialinsightsintothepathophysiologyoftremor AT hinmanjamesr pharmacologicalandphysiologicalcharacterizationofthetremulousjawmovementmodelofparkinsoniantremorpotentialinsightsintothepathophysiologyoftremor AT chrobakjamesj pharmacologicalandphysiologicalcharacterizationofthetremulousjawmovementmodelofparkinsoniantremorpotentialinsightsintothepathophysiologyoftremor AT senatuspatrickb pharmacologicalandphysiologicalcharacterizationofthetremulousjawmovementmodelofparkinsoniantremorpotentialinsightsintothepathophysiologyoftremor AT salamonejohnd pharmacologicalandphysiologicalcharacterizationofthetremulousjawmovementmodelofparkinsoniantremorpotentialinsightsintothepathophysiologyoftremor |